Science AI Journal
Medicine · Research topic

Open research questions in Endometrial and Cervical Cancer Treatments

500 gap statements mined from Endometrial and Cervical Cancer Treatments papers in our 7.9M-paper local library, which holds 3,255 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Endometrial and Cervical Cancer Treatments? See the ranked Medicine journals.

What the literature leaves open

  • The current standard of care involves definitive concurrent platinum-based chemoradiotherapy, but there is a need to explore treatment pathways and identify candidate correlates of surgical intervention.

    Treatment Pathways and Candidate Correlates of Surgical Intervention in Locally Advanced Cervical and Other Gynecological Cancers: A Hypothesis-Generating Single-Center Cohort Study · 2026 · DOI

  • Limited treatment options for patients with recurrent cervical cancer who experience progression after prior platinum-based systemic chemotherapy. Need for new treatment options with antitumor activity against cervical cancer.

    Clinical activity of platinum rechallenge with nedaplatin plus irinotecan in recurrent cervical cancer following prior platinum-based systemic chemotherapy: a single-center retrospective study · 2026 · DOI

  • The study had a moderate to high risk of bias in most included studies. Some studies excluded substantial numbers of patients due to incomplete treatment or missing data. The study had limited data on disease-free survival and progression-free survival.

    Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis · 2026 · DOI

  • The study identifies the challenge of achieving balance on metastatic sites due to sparse categories and limited overlap. The study notes the challenge of addressing competing risks in the analysis. The study mentions the challenge of interpreting the results in the context of clinical relevance and equivalence.

    Metastasis-Directed Therapy Versus Systemic Therapy in Oligometastatic Endometrial Carcinoma Recurrence: A Population-Based Registry Analysis · 2026 · DOI

  • There is a lack of comparative data on MDT versus systemic therapy in oligometastatic EC recurrence. The study aims to address this gap by comparing overall survival outcomes between MDT and systemic therapy.

    Metastasis-Directed Therapy Versus Systemic Therapy in Oligometastatic Endometrial Carcinoma Recurrence: A Population-Based Registry Analysis · 2026 · DOI

  • The need to consider multiple genetic conditions in a small percentage of EC patients. The challenge of interpreting abnormal p53 protein expression in tissue staining.

    Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection · 2024 · DOI

  • Although several studies have described the clinicopathological features of this pattern, the molecular alterations have not yet been explored.

    An Endometrioid Carcinoma With an Adenoma Malignum-like Pattern of Invasion: New Insight into Molecular Features · 2026 · DOI

  • Although molecular classification has improved risk stratification in endometrial carcinoma, the mutational profile of carcinosarcoma by heterologous versus homologous sarcomatous component is not well characterized.

    Uterine Carcinosarcoma: Mutational Profiling of p53-Abnormal Tumors and Its Association with Histologic Subtypes and Survival in an Underserved Population · 2026 · DOI

  • Prolonged overall treatment time (OTT) during definitive radiotherapy has long been considered detrimental in cervical cancer, but the magnitude and consistency of its prognostic association across treatment eras remain uncertain.

    Overall treatment time and oncologic outcomes after definitive radiotherapy or chemoradiotherapy for cervical cancer: a systematic review and meta-analysis · 2026 · DOI

  • As immunosuppression occurred with BMS VMAT, optimizing BMS and exploring other techniques is warranted.

    Dynamic immune changes after bone marrow sparing VMAT in women with locally advanced cervical cancer treated with chemoradiotherapy · 2026 · DOI

  • The role of metastasis-directed radiotherapy (MDRT) in oligometastatic cervical carcinoma (OCC) remains unclear.

    Metastasis-directed radiotherapy for oligometastatic cervical carcinoma: Identifying potential beneficiaries · 2026 · DOI

  • The benefit of rectal spacers in cervical cancer remains uncertain, particularly with MRI-guided adaptive brachytherapy (MR-IGABT).

    Dosimetric and clinical outcomes of hyaluronic acid rectal spacer in MRI-guided adaptive brachytherapy for cervical Cancer: A phase II randomized controlled trial · 2026 · DOI

  • Given the limitations of such database analyses, further exploration in molecularly defined cohorts is warranted.

    Improved Overall Survival Associated With Vaginal Cuff Brachytherapy Boost for Stage II Endometrioid Endometrial Cancer · 2026 · DOI

  • Endometrioid carcinoma with squamous differentiation (SqD) is morphologically heterogeneous, and the clinical significance of malignant SqD remains poorly defined.

    Endometrioid Carcinoma With Malignant Squamous Differentiation · 2026 · DOI

  • A trend towards higher yet tolerable acute and late GI toxicity warrants further investigation.

    Early Results of Hypofractionated Chemoradiation in Cervical Cancer with 44 Gy/ 20 F vs 45 Gy/ 25 F: A Phase II, Open-Label, Randomised Controlled Trial (HYPOCx-iRex Trial) · 2025 · DOI

  • Also, it is not well established whether low-grade tumors can belong to the p53 abnormal molecular subgroup and if so, what is the prognostic significance of the p53-mutated molecular subgroup in low-grade tumors.

    p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma · 2024 · DOI

  • Among the 4 molecular subgroups of endometrial carcinoma, the p53 abnormal (copy number high) subgroup has the worst prognosis; however, the histologic characteristics of this subgroup are not well established.

    p53 Abnormal (Copy Number High) Endometrioid Endometrial Carcinoma Has a Prognosis Indistinguishable From Serous Carcinoma · 2024 · DOI

  • Clinicopathologic overlap between PiMHEC and other high-grade endometrial cancers with SB-GN has not been established.

    High-grade Endometrial Carcinomas With Solid Basaloid Morphology and Geographic Necrosis Lacking Definitive Pilomatrix-like Features: Clinicopathologic Characteristics Including Aggressive Behavior and Novel Molecular Events · 2024 · DOI

  • The incorporation of molecular aspects into treatment decision-making is challenging. There is no standard cut-off value for positivity of estrogen receptor and progesterone receptor in tumor tissue.

    Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment · 2024 · DOI

  • Although HGI did not significantly reduce rectal D2cm 3 in this underpowered randomized trial, its dosimetric benefit remains inconclusive.

    Dosimetric and clinical outcomes of hyaluronic acid rectal spacer in MRI-guided adaptive brachytherapy for cervical Cancer: A phase II randomized controlled trial · 2026 · DOI

  • The survey was limited to clinicians in Australia, - The survey was distributed online and may not have reached all eligible clinicians, - The survey had a response rate of 56%, - There are no Australian-specific guidelines or registries for fertility-sparing treatment of endometrial…

    Fertility‐Sparing Treatment of Endometrial Cancer: Survey of Australian Practice · 2026 · DOI

  • Research on weight-loss as a priority theme, - Investigation of molecular markers and immunotherapy, - Study of the effectiveness of different management strategies for fertility-sparing treatment of endometrial cancer, - Examination of the role of POLE mutation testing in fertility-sparing…

    Fertility‐Sparing Treatment of Endometrial Cancer: Survey of Australian Practice · 2026 · DOI

  • Information on the simultaneous occurrence of POLEmut and dMMR is scarce - The clinical significance of TP53 alterations and their impact on tumorigenesis is a very complex…

    Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection · 2024 · DOI

  • Researching molecular-directed treatment strategies, - Evaluating the prognostic and predictive role of biomarkers in response to therapies, - Exploring the incorporation of molecular aspects into treatment…

    Tailoring Endometrial Cancer Treatment Based on Molecular Pathology: Current Status and Possible Impacts on Systemic and Local Treatment · 2024 · DOI

  • The subsequent endometrial curettings performed at our institution showed both the MLA and undifferentiated components, each of which demonstrated distinct immunophenotype with the immunoreactivity to epithelial markers, GATA3 and TTF1 limited to the MLA component and the aberrant nuclear expression of beta catenin, global loss of expression of SMARCA4 and loss of expression of SMARCA2 limited…

    A Case Report of Uterine Dedifferentiated Mesonephric-Like Adenocarcinoma With Comprehensive Molecular Profiling · 2025 · DOI

Most-cited papers in Endometrial and Cervical Cancer Treatments

Most recent work

Find a gap in your own Endometrial and Cervical Cancer Treatments sub-topic

This page shows what the Endometrial and Cervical Cancer Treatments literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,200 open questions
Dementia and Cognitive Impairment Research
2,789 open questions
Substance Abuse Treatment and Outcomes
2,285 open questions
Cancer Immunotherapy and Biomarkers
2,273 open questions
Liver Disease Diagnosis and Treatment
2,102 open questions
Sports Performance and Training
1,952 open questions
Parkinson's Disease Mechanisms and Treatments
1,915 open questions
Mosquito-borne diseases and control
1,849 open questions
Open questions raised by papers listed on this page include: (1) The current standard of care involves definitive concurrent platinum-based chemoradiotherapy, but there is a need to explore treatment pathways and identify candidate correlates of surgical intervention (“Treatment Pathways and Candidate Correlates of Surgical Intervention in Locally…”, 2026); (2) There is a lack of comparative data on MDT versus systemic therapy in oligometastatic EC recurrence (“Metastasis-Directed Therapy Versus Systemic Therapy in Oligometastatic…”, 2026); (3) Although several studies have described the clinicopathological features of this pattern, the molecular alterations have not yet been explored (“An Endometrioid Carcinoma With an Adenoma Malignum-like Pattern of Invasion:…”, 2026); (4) Although molecular classification has improved risk stratification in endometrial carcinoma, the mutational profile of carcinosarcoma by heterologous versus homologous sarcomatous component is not well characterized (“Uterine Carcinosarcoma: Mutational Profiling of p53-Abnormal Tumors and Its…”, 2026); (5) As immunosuppression occurred with BMS VMAT, optimizing BMS and exploring other techniques is warranted (“Dynamic immune changes after bone marrow sparing VMAT in women with locally…”, 2026). 500 gap statements have been mined from Endometrial and Cervical Cancer Treatments papers in our 7.9M-paper local library, which holds 3,255 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.